Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Shagun Singh Chadha
RBC
Shagun Singh Chadha
RBC Capital
Wall Street Analyst
★★★☆☆
#1723
on 13Foresight · ranked by our own returns
36%
Success Rate
-3.3%
Average Return
8 of 22 calls profitable · -6.1% vs benchmark
📈 Across the calls we could measure, roughly 36% of Shagun Singh Chadha's ratings turned a profit when each position was held for 1 year — averaging -3.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

166 Buy 47 Hold 0 Sell
Shagun's Stock Coverage 18 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
EW
Edwards Lifesciences
 Jun 15, 2026 BUY Strong Buy
+11.7% avg upside
34 analysts
$100.00
14.42% Upside
 +0.5%
PEN
Penumbra
 Jun 11, 2026 HOLD Buy
+4.5% avg upside
23 analysts
$374.00
17.93% Upside
 -0.7%
MDT
Medtronic
 Jun 03, 2026 BUY Buy
+23.7% avg upside
38 analysts
$118.00
48.63% Upside
 +1.8%
PODD
Insulet
 May 27, 2026 BUY Strong Buy
+79.3% avg upside
32 analysts
$280.00
92.09% Upside
 +2.5%
BSX
Boston Scientific
 May 27, 2026 BUY Strong Buy
+73.0% avg upside
38 analysts
$100.00
120.70% Upside
 -10.2%
DXCM
Dexcom
 May 15, 2026 BUY Strong Buy
+38.8% avg upside
32 analysts
$85.00
17.28% Upside
 +18.7%
TFX
Teleflex
 May 08, 2026 BUY Buy
+42.3% avg upside
19 analysts
$155.00
22.11% Upside
 -4.3%
OM
Outset Medical
 May 08, 2026 HOLD Buy
+231.0% avg upside
8 analysts
$7.00
38.70% Upside
 -1.9%
TNDM
Tandem Diabetes Care
 May 07, 2026 BUY Buy
+115.3% avg upside
29 analysts
$30.00
96.10% Upside
 -8.5%
BDX
Becton Dickinson
 May 07, 2026 HOLD Buy
+35.6% avg upside
25 analysts
$175.00
21.63% Upside
 -5.4%
GMED
Globus Medical
 May 07, 2026 BUY Strong Buy
+22.3% avg upside
24 analysts
$120.00
51.46% Upside
 -5.5%
INSP
Inspire Medical Systems
 May 04, 2026 HOLD Buy
+98.0% avg upside
20 analysts
$45.00
5.61% Upside
 -22.9%
SYK
Stryker
 May 01, 2026 BUY Strong Buy
+24.1% avg upside
36 analysts
$435.00
41.34% Upside
 +3.0%
ZBH
Zimmer Biomet Holdings
 Apr 28, 2026 BUY Buy
+27.6% avg upside
37 analysts
$101.00
14.87% Upside
 +7.2%
ISRG
Intuitive Surgical
 Apr 21, 2026 BUY Strong Buy
+29.5% avg upside
36 analysts
$650.00
59.83% Upside
 -9.9%
ABT
Abbott Laboratories
 Apr 16, 2026 BUY Strong Buy
+31.2% avg upside
35 analysts
$130.00
47.10% Upside
 -7.3%
JNJ
Johnson & Johnson
 Apr 14, 2026 BUY Strong Buy
-3.6% avg upside
36 analysts
$265.00
16.11% Upside
 -1.5%
IART
Integra Lifesciences
 Apr 29, 2021 HOLD Buy
+137.0% avg upside
21 analysts
$74.00
320.86% Upside
 -18.5%
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Shagun Singh Chadha — Frequently Asked Questions
How accurate are Shagun Singh Chadha's stock ratings?
Based on the calls 13Foresight could measure, about 36% of Shagun's ratings were profitable over a one-year hold, with an average return of -3.3% per rating, or -6.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Shagun ranked on 13Foresight?
Shagun Singh Chadha is currently ranked #1723 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Shagun cover?
Shagun most recently has ratings on EW, PEN, MDT, PODD, BSX, DXCM, TFX, OM, TNDM, BDX, GMED, INSP and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.